Johnson & Johnson's most recent trend suggests a bearish bias. One trading opportunity on Johnson & Johnson is a Bear Call Spread using a strike $160.00 short call and a strike $165.00 long call offers a potential 12.36% return on risk over the next 9 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $160.00 by expiration. The full premium credit of $0.55 would be kept by the premium seller. The risk of $4.45 would be incurred if the stock rose above the $165.00 long call strike price.
The 5-day moving average is moving down which suggests that the short-term momentum for Johnson & Johnson is bearish and the probability of a decline in share price is higher if the stock starts trending.
The 20-day moving average is moving down which suggests that the medium-term momentum for Johnson & Johnson is bearish.
The RSI indicator is at 34.04 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Johnson & Johnson
Russia Secures Sputnik Italy Output in European Vaccine Push
Tue, 09 Mar 2021 09:49:38 +0000
(Bloomberg) — Russia is pushing ahead with plans to make its Covid-19 vaccine in Europe, securing a deal to produce the Sputnik V shot in Italy and discussing production in Germany and France.Adienne Pharma & Biotech SA signed an agreement to manufacture the vaccine at its production site in the Milan region, Antonio Francesco Di Naro — the founder and president of the Lugano, Switzerland-based company — told Bloomberg in an interview.The deal with Russia’s sovereign wealth fund RDIF is the first European production deal for the vaccine. While Russia was first to approve a shot for the general public and promoted it as a way to help end the pandemic globally, it has been slower than some rivals to scale up output.The vaccine is under review by authorities in the European Union, which has struggled to ramp up inoculations amid a lack of supply. The sluggish rollout has prodded some countries to consider their own purchasing deals in a challenge to the bloc’s solidarity.“There are many Italian regions which are enthusiastic about having Sputnik, they would also want to produce it,” Kirill Dmitriev, chief executive officer of the state-run Russian Direct Investment Fund, told Italian Rai3 television on Sunday. “We have a partnership in Germany. We’re talking to several French companies.”Sputnik V’s developers have had contact with German vaccine maker IDT Biologika GmbH, according to IDT spokesman Ulrich Gartner, who confirmed a report by German broadcaster MDR. He said that the company cannot comment on the details of ongoing talks with potential customers.IDT, based in the state of Saxony-Anhalt, signed a letter of intent last month to help AstraZeneca Plc boost supply of its vaccine.Dmitriev, who is in charge of Sputnik’s international roll-out and backed its development, said in the Italian TV interview that production in the country could start in June. The timing depends on approval from Italian regulators, and Di Naro said he couldn’t set production targets as of now.The deal comes as Prime Minister Mario Draghi pledged to speed up Italy’s fledgling vaccination campaign amid a new rise in infections from the disease that’s led to more than 100,000 fatalities in the country.Draghi blocked the export of AstraZeneca’s vaccine earlier this month after the company sharply reduced planned deliveries to the EU. He was the first European leader to use the recently-introduced powers, highlighting the sensitivity in the region over the supply of Covid-19 shots.European Commission President Ursula von der Leyen on Monday lashed out at manufacturers for failing to uphold their commitments as countries in Europe struggle to step up the pace of inoculations.Officials are also bracing for delays in the delivery of a new vaccine from Johnson & Johnson, according to two people with knowledge of the process.The shots, which are due to be approved by the European Medicines Agency this week, were due to start arriving at the beginning of April but now aren’t expected until the middle of the month at the earliest, one of the officials said.The EU has administered 9.35 doses per 100 people, compared with nearly 28 for the U.S. and more than 35 for the U.K., according to Bloomberg’s Coronavirus Vaccine Tracker.The European Medicines Agency said March 4 that it started a rolling review of Sputnik V to test compliance with safety and quality standards, the first major step in gaining approval for use in the European Union. The Russian vaccine started to gain broader international recognition after The Lancet medical journal published peer-reviewed results of interim trials showing 91.6% efficacy.Despite the progress, it’s unclear what role political tension would play in the distribution of the Sputnik vaccine in Europe. Tensions between Russia and the EU have deteriorated further in recent months, especially after the jailing of opposition leader Alexey Navalny.In a sign of the tensions, the shot’s developer took to Twitter to demand an apology from an EMA official over comments that “raise serious questions about possible political interference” in the agency’s review.Christa Wirthumer-Hoche, EMA’s management board chairwoman, told Austrian broadcaster ORF late Sunday that national emergency authorizations are like “Russian roulette.”Pfizer Vaccine Beats Variants; Global Cases Rise: Virus Update(Updates with IDT spokesman, detail on J&J vaccine from sixth paragraph)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.
Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
Mon, 08 Mar 2021 22:45:10 +0000
Johnson & Johnson (JNJ) closed the most recent trading day at $157.40, moving +0.83% from the previous trading session.
‘Trust is an underlying issue’ in families of color sending children back to school: CEO of Baltimore City Public Schools
Mon, 08 Mar 2021 20:34:35 +0000
Dr. Sonja Santelises, CEO of Baltimore City Public Schools, joins Yahoo Finance’s Alexis Christoforous and Akiko Fujita to discuss the push to reopen schools and women in education.
Momentum ETFs to Gain From the New Stimulus Optimism
Mon, 08 Mar 2021 20:00:08 +0000
Here we highlight some momentum ETFs that are lucrative investment picks keeping in mind the optimism surrounding Wall Street.
Fmr. White House Doctor: It’s ‘ill advised’ to relax COVID-19 mandates amid spreading variants
Mon, 08 Mar 2021 19:03:23 +0000
Dr. Jennifer Pena, Nurx Chief Medical Officer & Former White House Medical Unit Physician for Obama, Biden and Pence, joins Yahoo Finance’s Julie Hyman and Alexis Christoforous to discuss the latest coronavirus updates and women in medicine.
Also on Market Tamer…
Follow Us on Facebook